Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: An open-label, randomized study in adults aged 18-60 years and older

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 7, 2013, Pages 1512-1522

  Van Damme, Pierre ^a   Kafeja, Froukje ^a   Bambure, Vinod ^b   Hanon, Emmanuel ^c   Moris, Philippe ^c   Roman, François ^c   Gillard, Paul ^c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b GlaxoSmithKline Pharmaceuticals Ltd   (India)

^c GSK   (Belgium)

Author keywords

Cellular immune response; H1N1; Long term; Persistence

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; HEMAGGLUTININ ANTIGEN AS03 ADJUVANTED H1N1 2009 INFLUENZA VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADULT; AGED; BREAST CANCER; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FRACTURE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOREGULATION; INFECTION PREVENTION; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; PNEUMOTHORAX; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SUBDURAL HEMATOMA; UNSPECIFIED SIDE EFFECT;

CELLULAR IMMUNE RESPONSE; H1N1; LONG-TERM; PERSISTENCE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; VACCINATION; YOUNG ADULT;

EID: 84880915260     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24504     Document Type: Conference Paper

References (25)

1. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-5; PMID:20034605; http://dx.doi.org/10.1016/j.vaccine.2009.12.014.
2. Carmona A, Omeñaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010; 28:5837-44; PMID:20600478; http://dx.doi.org/10.1016/j.vaccine.2010.06.065.
3. Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Maeda A, et al. Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum Vaccin 2010; 6:888-93; PMID:20980795; http://dx.doi.org/10.4161/hv.6.11.12851.
4. Roman F, Clément F, Dewé W, Walravens K, Maes C, Willekens J, et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011; 18:835-43; PMID:21450978; http://dx.doi.org/10.1128/CVI.00480-10.
5. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668-77; PMID:20687838; http://dx.doi.org/10.1086/655830.
6. Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012; 205:733-44; PMID:22315336; http://dx.doi.org/10.1093/infdis/jir641.
7. Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03Aadjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011; 11:91-101; PMID:21168369; http://dx.doi.org/10.1016/S1473-3099(10)70296-6.
8. Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nøstbakken JK, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2010; 29:266-73; PMID:21034828; http://dx.doi.org/10.1016/j.vaccine.2010.10.038.
9. Saitoh A, Tamura S, Nagai A, Tsuchida N, Sako M, Maekawa T, et al. Clinical evaluation of an AS03-adjuvanted pandemic influenza H1N1 2009 vaccine in children (Preliminary report). [Japanese.]. J Jap Pediatr Soc 2011; 115:578-84.
10. Saitoh A, Nagai A, Tenjinbaru K, Li P, Vaughn DW, Roman F, et al. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years. Hum Vaccin Immunother 2012; 8:749-58; PMID:22495117; http://dx.doi.org/10.4161/hv.19684.
11. Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849-57; PMID:19835828; http://dx.doi.org/10.1016/j.vaccine.2009.10.017.
12. Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008; 26:6383-91; PMID:18801398; http://dx.doi.org/10.1016/j.vaccine.2008.08.046.
13. Cowling BJ, Ng S, Ma ES, Cheng CK, Wai W, Fang VJ, et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis 2010; 51:1370-9; PMID:21067351; http://dx.doi.org/10.1086/657311.
14. National Institute of Allergy and Infectious Diseases (NIAID). Early Results: NIAID Trial Supports Co-Administration of 2009 H1N1 Influenza Vaccine and Seasonal Influenza Vaccine Bulletin 2009; October 09, 2009. Available: http://www.niaid.nih.gov/news/newsreleases/2009/pages/h1n1plusseasonalvax.aspx. Accessed: February 20, 2012.
15. Regner S, Peeters M, Schmitt B, Vaman T, Devaster JM, Rombo L. Immunogenicity, safety and reactogenicity of the AS03A-adjuvanted influenza A (H1N1) 2009 vaccine following sequential or co-administration with a licensed seasonal trivalent vaccine in adults aged ≥ 61 years. Accepted to be presented at the XIII International Symposium on Respiratory Viral Infections 2011, 13-16 March 2011, Rome, Italy.
16. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010; 375:49-55; PMID:20018367; http://dx.doi.org/10.1016/S0140-6736(09)62039-0.
17. Ikematsu H, Tenjinbaru K, Li P, Madan A, Vaughn D. Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. Hum Vaccin Immunother 2012; 8:1119-25; PMID:22854661.
18. Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Li P, et al. Characterization and longterm persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Hum Vaccin Immunother 2012; 8:260-6; PMID:22426369.
19. Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines 2008; 7:467-79; PMID:18444893; http://dx.doi.org/10.1586/14760584.7.4.467.
20. GlaxoSmithKline (GSK) Biologicals. Pandemrix™ suspension and emulsion for emulsion for injection. Summary of product characteristics. March 02, 2010.
21. Hehme NW, Künzel W, Petschke F, Gisela T, Carmen R, Christian Van H, et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Investig 2002; 22:751-69; http://dx.doi.org/10.2165/ 00044011-200222110-00004.
22. European Committee for Proprietary Medicinal Products (CHMP). Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, January 24, 2007.
23. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9; PMID:17707753; http://dx.doi.org/10.1016/S0140-6736(07) 61297-5.
24. Yang H, Carney P, Stevens J. Structure and Receptor binding properties of a pandemic H1N1 virus hemagglutinin. PLoS Curr 2010; 2:RRN1152; PMID:20352039; http://dx.doi.org/10.1371/currents.RRN1152
25. Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-54; PMID:21174144; http://dx.doi.org/10.1007/s10875-010-9490-6.